HC Wainwright Reiterates Buy Rating for Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $65.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 225.81% from the company’s previous close.

A number of other equities research analysts also recently weighed in on JSPR. Royal Bank of Canada lowered their price target on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 14th. Stifel Nicolaus initiated coverage on Jasper Therapeutics in a research report on Thursday, June 27th. They issued a “buy” rating and a $86.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. BTIG Research initiated coverage on shares of Jasper Therapeutics in a research report on Monday, July 8th. They issued a “buy” rating and a $90.00 target price on the stock. Finally, Evercore ISI reissued an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 26th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $74.86.

Jasper Therapeutics Trading Down 0.6 %

JSPR stock opened at $19.95 on Thursday. The firm has a 50 day moving average of $19.31 and a 200-day moving average of $21.22. The firm has a market capitalization of $300.53 million, a P/E ratio of -3.54 and a beta of 2.21. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. Sell-side analysts predict that Jasper Therapeutics will post -4.16 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wolff Wiese Magana LLC bought a new stake in shares of Jasper Therapeutics in the 3rd quarter worth approximately $59,000. Virtu Financial LLC purchased a new stake in shares of Jasper Therapeutics during the first quarter valued at $306,000. Rhumbline Advisers bought a new stake in Jasper Therapeutics in the 2nd quarter worth about $300,000. American Century Companies Inc. raised its position in Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in Jasper Therapeutics during the 1st quarter valued at about $599,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.